Cholesterol oxidation products induce vascular foam cell lesion formation in hypercholesterolemic New Zealand white rabbits.
Circulating cholesterol oxidation products (ChOx) have long been implicated in the etiology of early atherosclerosis; however, direct in vivo evidence elucidating their role in atherogenesis is only recently becoming available. This study investigated ChOx effects on vascular lesion formation in New Zealand White rabbits under controlled hypercholesterolemic conditions. By closely monitoring plasma cholesterol levels and adjusting dietary cholesterol intake during a 78-day period, total plasma cholesterol exposures (cumulative plasma cholesterol levels over time) were controlled between 27 000 and 34 000 mg/dLxday (final plasma cholesterol concentration, 467+/-77 mg/mL), representing a threshold range for sudanophilic lesion formation in the aorta. Twenty injections of a ChOx mixture (70 mg per injection) were made bearing an oxysterol composition similar to that found in circulating oxidatively modified low density lipoprotein. At sacrifice, the ChOx-injected rabbits (n=5) had (1) significantly higher plasma ChOx levels, (2) significantly increased cholesterol content in the aortas, mainly as esterified cholesterol, and (3) significantly greater sudanophilic lesion size and frequency in the aortas compared with vehicle-injected control rabbits (n=5). The aortic cholesterol content and extent of sudanophilic lesion area were correlated significantly with total plasma ChOx exposure (P<0.003 and P<0.0001, respectively) but not with total cholesterol exposure. The results indicate that for moderate experimental hypercholesterolemia, a situation more relevant to physiological hypercholesterolemia in humans, circulating ChOx may play an important role in inducing formation of early atherosclerotic lesions. Because ChOx are often present in cholesterol-containing diets, foam cell lesion formation induced by ChOx rather than cholesterol cannot be overlooked.
Rong
J X
JX
Department of Pathology, School of Medicine, University of Southern California, Los Angeles, USA.
Shen
L
L
Chang
Y H
YH
Richters
A
A
Hodis
H N
HN
Sevanian
A
A
D000818:Animals; D001011:Aorta / Q000378:metabolism* / Q000473:pathology*; D001391:Azo Compounds; D002784:Cholesterol / Q000097:blood / Q000378:metabolism*; D002788:Cholesterol Esters / Q000378:metabolism; D002914:Chylomicrons / Q000097:blood; D004396:Coloring Agents; D005487:Foam Cells / Q000473:pathology*; D006937:Hypercholesterolemia / Q000097:blood / Q000378:metabolism* / Q000473:pathology*; D008099:Liver / Q000378:metabolism; D008297:Male; D010084:Oxidation-Reduction; D011817:Rabbits
D001391:Azo Compounds; D002788:Cholesterol Esters; D002914:Chylomicrons; D004396:Coloring Agents; D002784:Cholesterol; C009213:Scarlet Red